Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Assessing for Coronary Microvascular Dysfunction (CMD)
Cath CMD

CATH CMD is a global algorithm that captures the essential details of performing the bolus thermodilution workflow and assists in decision-making in a simple and stepwise manner. In summary, CATH captures the how to perform bolus thermodilution and CMD captures the what to do with the Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) measurements to provide a diagnosis of Coronary Microvascular Dysfunction (CMD).

A comprehensive physiology assessment (with Resting full-cycle Ratio (RFR), Fractional Flow Reserve (FFR), IMR and CFR) of the epicardial arteries and the microvasculature can provide patients with persistent angina an accurate diagnosis to improve outcomes.1

Video How to Assess and Diagnose Coronary Microvascular Dysfunction with CATH CMD
CATH CMD Algorithm
Download CMD Algorithm

Catheter Engagement

  • Flush thoroughly2
  • Coaxial guide engagement2
  • Ensure no damping2
CATH CMD Catheter Engagement

Advance Wire

  • Interrogate LAD unless there is a specific territory of interest1
  • Advance wire sensor 2/3 distally in vessel3
  • Administer GTN/NTG2
CATH CMD Wire Advancement

Transit Time at Rest

  • Flush/purge pre-Tmnrest to clear any blood and contrast3
  • Room temperature saline3
  • Brisk 3 mL x 3 injections3
  • Address outliers (± 0.15s) before proceeding*4

*Repeat measurement of Tmnrest

CATH CMD Transit Time

Hyperemic Transit Time

  • Induce hyperemia5
  • Confirm hyperemia*6
  • Flush/purge pre-Tmnhyp to clear any blood and contrast6
  • Room temperature saline6
  • Brisk 3 mL x 3 injections6
  • Address outliers (± 0.15s) before proceeding**4

*Decrease in pressure, patient symptoms, FFR drop
**Repeat measurement of Tmnhyp

CATH CMD Hyperemic Transit Time

Coronary Flow Reserve (CFR)

  • CFR <2.5*4
  • CFR grey zone 2.0-2.4*

*Evolving concensus

CATH CMD Coronary Flow Reserve (CFR)

Index of Microcirculatory Resistance (IMR)

  • IMR ≥251
  • Use IMRcorr if FFR ≤0.807
CATH CMD Index of Microcirculatory Resistance (IMR)

Diagnosis

  • Diagnosis of CMD based on IMR ≥25 and CFR <2.5*1,4
  • CFR grey zone 2.0-2.4*
  • Refer to guidelines and consensus document1,4,8,9

*Evolving consensus

CATH CMD Coronary Microvascular Dysfunction Diagnosis

GTN (glyceryl trinitrate) | NTG (nitroglycerin) | LAD (left anterior descending) | FFR (fractional flow reserve) | IMRcorr (IMR corrected) | CMD (coronary microvascular dysfunction) | Tmnrest (resting transit mean time) | Tmnhyp (hyperemic transit mean time)

References

  1. Kunadian V, et al. EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries. EHJ. 2020; 0, 1-21.
  2. Berry C. Fractional Flow Reserve, Coronary Flow Reserve and the Index of Microvascular Resistance in Clinical Practice. Radcliffe Cardiology. 2014, 1-6.
  3. Fearon W, et al. Invasive Assessment of the Coronary Microvasculature: The Index of Microcirculatory Resistance. Circ Cardiovasc Interv. 2017; 10:e005361
  4. Perera D, et al. Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease. Heart. 2022; 0, 1-8.
  5. Ford T, et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. JACC. 2018, 72, 2841-55.
  6. Ang D, et al. Interventional Diagnostic Procedure: a Practical Guide for the Assessment of Coronary Vascular Function. JOVE 2022; 181, e2265.
  7. Yong A, et al. Calculation of the Index of Microcirculatory Resistance Without Coronary Wedge Pressure Measurement in the Presence of Epicardial Stenosis. JACC: Cardiovasc Interv. 2013; 6, 53-8.
  8. Knuuti J, et al. ESC guidelines. EHJ. 2020; 41, 407-477.
  9. Gulati M, et al. 2021 Chest Pain Guideline, Circulation. 2021; 144, e368-e454.
Request Abbott Sales Rep

MAT-2211746 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo